Aptagen, LLC
* The secondary structure may not be accurate because of MFOLD limitations on chemistries other than RNA/DNA.
Peptide
VEGF-Stimulated human umbilical vein endothelial cells (HUVECs)
Protein
N/A nM (reported value)
In vivo mice.
N/A°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Contains WAR epitope believed to suppress migration of VEGF-stimulated HUVECs, resulting in suppression of tumor growth.
See also ASS peptide , which also results in suppression of tumor growth.
See also PVV peptide , which is mentioned in the same article, and also results in tumor growth suppression.
VEGF-Stimulated HUVECs (ID# 354)
See also ASS peptide , which also results in suppression of tumor growth.
See also PVV peptide , which is mentioned in the same article, and also results in tumor growth suppression.
5'AspArgTrpArgProAlaLeuProValValLeuPheProLeuHis3'
15
2006.41 g/mole
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Asai et al. "Isolation of a Novel Peptide Homing to Tumor-Derived Neovasculature That Suppresses Tumor Growth." Biological Pharmaceutical Bulletin, 25(2002): 904-906.
Have your aptamer oligo synthesized ORDER NOW
We are always looking for ways to improve. Please tell us what you think.